The Brazil genetic testing market size reached USD 421.61 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 962.06 Million by 2033, exhibiting a growth rate (CAGR) of 9.60% during 2025-2033. The rising awareness of genetic disorders, increasing adoption of personalized medicine, expanding genomic research, continual technological advancements, growing government initiatives, the rising demand for pre- and post-natal genetic screening are some of the major factors positively impacting the Brazil genetic testing market share.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 421.61 Million |
Market Forecast in 2033 | USD 962.06 Million |
Market Growth Rate (2025-2033) | 9.60% |
Increasing awareness of genetic disorders and testing services
The rising consciousness among the masses regarding genetic disorders is driving Brazil's genetic market growth. Moreover, the growing education campaign and programs, which aim at creating awareness of hereditary diseases and the correctness of genetic susceptibility tests, are supporting the growth of the market. Governmental and non-profit organizations are also contributing significantly to awareness creation. On December 9, 2024, researchers from the São Paulo State Cancer Institute (ICESP) published a study identifying pathogenic germline variants (PGVs) in 6.25% of 192 Brazilian patients with pancreatic ductal adenocarcinoma. An additional 13% of patients exhibited PGVs in genes not previously associated with the disease. This research enhances our understanding of the genetic factors contributing to pancreatic cancer in Brazil. Increasing research activities creates awareness among individuals and ensures popular health checkups for diseases such as cancer, cardiovascular diseases, and genetic disorders. Furthermore, advancements in accessing healthcare information have increased consumer knowledge and actions toward prevention, leading to genetic testing becoming a common topic in healthcare conversations in Brazil. The increased demand for timely identification and customized treatment strategies is a key driver of market growth, especially with the integration of genetic testing by healthcare providers for long-term health management.
Growing adoption of personalized medicine
The development of the genetic testing market in Brazil is creating a positive Brazil genetic testing market outlook. Doctors are now using genetic testing in order to develop individual programs geared toward patients based on their genes. This approach makes the therapies more effective, reducing side effects and outcomes for the patient. Genetic testing as a part of personalized medicine continues to show a healthy uptake and is increasingly being applied across civilizations and specialties with a focus on oncology, cardiology & neurology. With advancements in genomic technologies, healthcare providers are offering more precise diagnoses and therapeutic recommendations. Moreover, individualized medicine is becoming increasingly important for handling intricate and long-lasting illnesses. Furthermore, precision health is increasing in popularity and fostering collaboration between genetics testing laboratories and pharmaceutical companies, further providing a boost to the popularity of genetic testing services. On December 4, 2024, MGI Tech Co., Ltd. announced a partnership with Sabin Group to enhance personalized medicine in Brazil by providing advanced genomic solutions for oncological and germline testing. This collaboration aims to improve the accessibility and quality of genetic testing services across the country. The agreement signifies a strategic effort to integrate cutting-edge sequencing technologies into Brazil's healthcare infrastructure.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on test type, disease, technology, service provider, and sample testing.
Test Type Insights:
The report has provided a detailed breakup and analysis of the market based on the type. This includes prenatal testing, carrier testing, new born testing, predictive/presymptomatic testing, diagnostic testing, and others.
Disease Insights:
A detailed breakup and analysis of the market based on the disease have also been provided in the report. This includes cancer, down syndrome, thalassemia, and others.
Technology Insights:
The report has provided a detailed breakup and analysis of the market based on the technology. This includes bio chemical, molecular, and cytogenetic.
Service Provider Insights:
A detailed breakup and analysis of the market based on the service provider have also been provided in the report. This includes hospital based, independent laboratories, and speciality clinics.
Testing Sample Insights:
The report has provided a detailed breakup and analysis of the market based on the sample testing. This includes blood, saliva, hair and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Southeast, South, Northeast, North, and Central-West.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered | Prenatal Testing, Carrier Testing, New Born Testing, Predictive/presymptomatic Testing, Diagnostic Testing, Others |
Diseases Covered | Cancer, Down Syndrome, Thalassemia, Others |
Technologies Covered | Bio Chemical, Molecular, Cytogenetic |
Service Providers Covered | Hospital Based, Independent Laboratories, Specialty Clinic |
Testing Samples Covered | Blood, Saliva, Hair, Others |
Regions Covered | Southeast, South, Northeast, North, Central-West |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: